Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Receivables (2019 - 2024)

Historic Receivables for Pliant Therapeutics (PLRX) over the last 6 years, with Q4 2024 value amounting to $2.3 million.

  • Pliant Therapeutics' Receivables fell 2318.99% to $2.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.3 million, marking a year-over-year decrease of 2318.99%. This contributed to the annual value of $2.3 million for FY2024, which is 2318.99% down from last year.
  • Latest data reveals that Pliant Therapeutics reported Receivables of $2.3 million as of Q4 2024, which was down 2318.99% from $3.0 million recorded in Q4 2023.
  • In the past 5 years, Pliant Therapeutics' Receivables ranged from a high of $18.6 million in Q4 2020 and a low of $1.6 million during Q3 2021
  • Over the past 5 years, Pliant Therapeutics' median Receivables value was $2.7 million (recorded in 2021), while the average stood at $4.8 million.
  • As far as peak fluctuations go, Pliant Therapeutics' Receivables tumbled by 8868.67% in 2021, and later surged by 19010.93% in 2022.
  • Over the past 5 years, Pliant Therapeutics' Receivables (Quarter) stood at $18.6 million in 2020, then tumbled by 87.17% to $2.4 million in 2021, then grew by 28.45% to $3.1 million in 2022, then fell by 2.09% to $3.0 million in 2023, then dropped by 23.19% to $2.3 million in 2024.
  • Its last three reported values are $2.3 million in Q4 2024, $3.0 million for Q4 2023, and $2.0 million during Q3 2023.